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Abstract
The management of muscle invasive bladder cancer represents an unresolved clinical challenge. Invasive urothelial carcinomas are asso-
ciated with high mortality rates and early metastatic disease. Radical cystectomy is a recognized standard of care, although disease-free 
survival outcomes remain suboptimal. The limitations of pre-operative clinical staging, as well as the complex natural history of the 
disease, precludes the introduction of simple management protocols. To what degree chemotherapy and radiotherapy may be useful in 
the surgical management of invasive bladder cancer remains contentious. This literature review critically examines the benefits, risks and 
difficulties of each approach, with an emphasis on individually tailored therapy.
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Introduction
Bladder cancer is the fourth most common malignancy in men 
and the ninth most common in women, with an estimated in-
cidence of 32.5 per 100,000 in the West.1 The overwhelming ma-
jority of bladder cancers in this population arise from urothelial 
epithelium; approximately 90% are transitional cell carcinomas 
(TCC). Rarely, squamous cell carcinoma or adenocarcinoma 
may be seen, in 7% and 2% of cases respectively (although 
their prevalence is subject to certain geographical parameters). 
The etiology of bladder cancer remains controversial and va-
rious risk factors have been identified, discussed elsewhere.2, 
3 Patients are typically elderly (>65 years) and male: few cases 
are seen below the age of 50 and men are four times more 
likely to develop the condition.4
The management of bladder cancer remains controversial. In-
deed, falling bladder cancer incidence over the last two deca-
des has not been associated with universal improvements in 
mortality.5 This literature review will critically appraise the use 
of chemotherapy and radiotherapy in the surgical management 
of muscle invasive bladder cancer. Multimodal therapies for 
non-invasive and metastatic disease fall beyond the scope of 
this topic. Similarly, specific surgical approaches will only be 
discussed where appropriate.
Search Strategy and Selection Criteria
A literature review was performed using PubMed, MEDLINE, Science 
Direct, Scopus and Embase databases using the search terms ‘muscle 
invasive bladder cancer’, ‘radical cystectomy’, ‘bladder-sparing surgery’ 
and ‘chemotherapy/radiotherapy for bladder cancer’. Randomized stu-
dies, reviews and consensus guidelines were included. Additional re-
levant papers were retrieved from the references. All included articles 
were in the English language. This review follows the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement.6
Stage and Grade
The primary determinant of prognosis is the stage and grade of 
the lesion, with lesser concern given to size and multicentricity for 
muscle invasive disease.7 Clinical staging is based upon a standard 
TNM classification system.8 Most tumours (~70%) are non-muscle in-
vasive and, of these, about 70% are confined to the bladder mucosa.
T2 lesions and above are described as ‘invasive’, having infiltrated 
the superficial muscle layer at least. Muscle invasion is related to 
significantly worse outcomes: the natural history (without treat-
ment) in ~85% of cases is death within two years.9 Additionally, 
the probability of nodal and metastatic disease is appreciably in-
creased – around 5% of patients present with metastatic deposits. 
The TNM system for bladder cancer is outlined in Table 1.8
The accuracy of available methods for determining the degree of muscle 
invasion pre-operatively is relatively poor. In fact, the correlation between 
depth of invasion on cystoscopy and biopsy reports is only in the re-
gion of 70%.10 The limitations of clinical staging are further illustrated in a 
study of 778 consecutive patients treated with radical cystectomy and pel-
vic lymphadenectomy: histological up-staging occurred in 42% of patients 
and down-staging in 22%.11 However, tissue diagnoses themselves are not 
always reliable and there remains a significant risk of under-staging fo-
llowing initial resection. Indeed, some studies report that 4-25% of tumours 
originally classified as non-muscle invasive are actually muscle invasive.12,13
The detection of lymph node involvement using imaging techniques is 
similarly poor. About 20-30% of patients with node negative disease ac-
cording to computerised tomography (CT) criteria will have pathologi-
cally positive specimens at lymphadenectomy.14 Conversely, a propor-
tion of cases with apparently node positive disease on CT or magnetic 
resonance imaging (MRI) will be downgraded at the time of surgery. An 
appreciation of these limitations may influence the relative authority 
given to surgery over chemotherapy or radiotherapy regimens.
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Both CT and MRI scans may be used to assess local invasion, althou-
gh both techniques only reliably detect T3b (extra-vesical) disease 
or above.15 Some debate has surrounded the relative authority given 
to MRI over CT; however, the greater soft tissue contrast afforded 
by the former now means it is the imaging modality of choice. For 
example, the accuracy of MRI in primary tumour staging is in the 
region of 85%, some 20% higher than CT.16 There may also be a role 
for fast dynamic contrast-enhanced MRI, especially in differentiating 
tumour from post-biopsy reactive changes.17 To avoid this, current 
consensus suggests that imaging be undertaken before resection in 
cases where muscle invasion is suspected.18  
Treatment Options for Muscle Invasive Bladder Cancer
Surgery
Radical cystectomy with lymphadenectomy represents a recog-
nized curative standard of care for muscle invasive disease, or 
high-risk superficial carcinoma unresponsive to conservative 
treatment. Bladder-preserving alternatives will not be discus-
sed here, except to highlight that these conventionally employ 
a multimodal approach in which surgical resection is supported 
by post-operative chemoradiotherapy.19
Epidemiological studies repeatedly demonstrate that radical cystec-
tomy produces the best outcomes, with recurrence free survival at 
five years most marked in organ-confined invasive cancer.20,21 Impor-
tantly, early cystectomy within a three-month window is associated 
with improved survival. In a subgroup analysis of patients with T2 
carcinoma, one study showed significantly less progression to lymph 
node positive disease (12% vs. 26%; p<0.013) and enhanced five-year 
disease-specific survival (80% vs. 56%, p<0.0006) following prompt 
surgical treatment.20 Within this 12-week timeframe, however, there 
appears to be no additional benefit of earlier local therapy.21
The factors influencing the type of urinary diversion offered are be-
yond the scope of this review; however, a recent Cochrane report su-
ggests that no particular technique is convincingly superior.22 Crucia-
lly, the type of reconstructive approach used has no significance with 
regards to whether chemotherapy or radiotherapy can be offered.3
The benefits of an initial surgical approach typically relate to tumour 
debulking and relief of local symptoms. Perhaps more importantly, 
surgical resection allows for definitive pathological staging. A larger, 
more recent trial to that discussed earlier demonstrated misleading 
clinical staging in 68% of the 3393 patients assessed.11,23 Removed 
specimens may be used to establish chemosensitivity profiles, or to 
stratify the patient into specific risk groups (so as to better inform 
their decision as to whether to opt for additional therapies). For 
example, those with pT2 TCC can expect up to 80% recurrence free 
survival at five years without additional chemotherapy or radiothe-
rapy.24 Prompt tissue diagnosis is therefore beneficial in this regard.
Chemotherapy: Neoadjuvant chemotherapy
Most bladder cancer patients usually succumb to distant disea-
se. Long-term follow-up of radical cystectomy patients suggests 
that, despite adequate local control, overall survival for muscle 
invasive TCC is suboptimal. Only 52-77% of pT2, 40-64% of pT3 
and 26-44% of pT4 individuals can expect to survive five years 
post-surgery.24 Occult micrometastatic disease during definitive 
local therapy is thought to underlie these unsatisfactory out-
comes; hence, a key benefit of pre-operative chemotherapy is 
that it may permit early treatment of outlying disease. 
Neoadjuvant chemotherapy also allows for an in vivo assessment 
of tumour response (possibly leading to down-staging and rever-
sion to bladder-sparing surgical options in a subset of patients). 
In one study of 111 patients with invasive TCC, 54% showed clear 
transurethral biopsies following MVAC (methotrexate, vinblasti-
ne, doxorubicin and cisplatin) therapy.25 These 60 patients were 
then allowed to choose between follow-up transurethral survei-
llance (n=28), partial cystectomy (n=15) or radical cystectomy 
(n=17). Of the 43 who opted for bladder-sparing options, 74% 
were alive at ten years and 58% were fully continent. However, 
56% developed recurrence and 13 cases required salvage cystec-
tomy. These data demonstrate that the majority of locally advan-
ced carcinomas responsive to chemotherapy are candidates for 
bladder-sparing intervention at a known risk of recurrence and, 
of these, most can be treated with salvage cystectomy.
Patient reported outcome measures suggest that conservative, 
bladder-sparing approaches are preferable to radical cystectomy. 
A questionnaire-based study of 59 patients demonstrated impro-
ved quality-of-life measures in all parameters assessed, the majo-
rity of these trends reaching statistical significance.26 Thus, neoad-
juvant treatment followed by bladder-preservation qualifies as a 
recognized standard of care for a subset of eligible patients. This 
may be offered to selected patients for their own consideration.
Primary Tumour (T)
   TX Primary tumour cannot be assessed
   T0 No evidence of primary tumour
   Ta Non-invasive papillary carcinoma
   Tis Carcinoma in situ: "flat tumour"
   T1 Tumour invades subepithelial connective tissue
   T2 Tumour invades muscularis propria
     pT2a Tumour invades superficial muscularis propria (inner half)
     pT2b Tumour invades deep muscularis propria (outer half)
   T3 Tumour invades perivesical tissue:
     pT3a Microscopically
     pT3b Macroscopically (extravesical mass)
   T4 Tumour invades extravesical structures
     T4a Tumour invades prostatic stroma, uterus, vagina
     T4b Tumour invades pelvic wall, abdominal wall
Regional Lymph Nodes (N)
   NX Lymph nodes cannot be assessed
   N0 No lymph node metastasis
   N1 Single regional lymph node metastasis in the true pelvis
   N2 Multiple regional lymph node metastases in the true pelvis
   N3 Lymph node metastases to the common iliac lymph nodes
Distant Metastases (M)
   M0 No distant metastasis
   M1 Distant metastasis
 Histological Grade (G)
   GX Grade cannot be assessed
   G1 Well differentiated
   G2 Moderately differentiated
   G3 Poorly differentiated or undifferentiated
Table 1. TNM Stage & Grade Classification.9
Source: Used with permission of the American Joint Committee on Cancer (AJCC), Chi-
cago, Illinois. The original and primary source for this information is the AJCC Cancer 
Staging Manual, Seventh Edition (2010) published by Springer Science+Business Media.
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Even if bladder sparing does not become feasible, chemotherapy in 
the neoadjuvant setting appears to be largely beneficial. For exam-
ple, the 1999 European Organization for Research and Treatment of 
Cancer (EORTC) Study suggests that pre-interventional chemotherapy 
is of value in both radical cystectomy and radical radiotherapy pa-
tients.27 Median survival of patients randomised to the chemothera-
py group increased from 37.5 months to 44 months following three 
cycles of CMV (cisplatin, methotrexate and vinblastine). Despite a 
higher incidence of pathological complete response in the treatment 
arm and this trend towards longevity, the failure to achieve a pre-
defined 10% survival improvement criterion meant that these data 
were originally reported as unsuccessful. Importantly, however, se-
ven-year delayed follow-up revealed a statistically significant hazard 
ratio (HR) of 0.85 in favour of chemotherapy. The later US Intergroup 
Trial (SWOG 8710) showed similar improvements in life expectancy: 
on intention-to-treat analysis of the 317 patients enrolled and ran-
domised, pre-operative MVAC therapy appeared to extend median 
survival time (46 months vs. 77 months; p=0.06).28 Advantageous 
outcomes were strongly associated with clear cystoscopy specimens 
in both treatment and control groups – of those with pT0 at the 
time of radical cystectomy, 85% were alive at five years. Pathological 
complete response was in the region of 38% for MVAC candidates 
– compared to just 15% in the surgery alone control arm – strengthe-
ning the causal link between chemotherapy and improved survival. 
Two consecutive trials from the Nordic Urothelial Cancer Group 
further validate pre-operative chemotherapy.29 Five-year survi-
val in the treatment arm increased from 48% to 56%, corres-
ponding to an absolute risk reduction of 8% and a beneficial 
HR of 0.80. However, subgroup analysis of patients according 
to T stage, gender or age revealed no significant differences, 
thus making it impossible to select which patients are most 
likely to benefit. However, as these studies tended to recruit 
younger patients with good renal function and better cancer 
performance status, their conclusions require rigorous scrutiny.
Overall, the data substantiate a direct link between platinum-based 
combination neoadjuvant chemotherapy and improved survival mea-
sures. Several meta-analyses have since been published, all of which 
support a modest – but significant – effect. For example, retrospective 
analysis of 2688 patients collated from 10 studies generated a favou-
rable HR of 0.87 (p=0.016), regardless of the local therapy employed.30 
This translates into a survival advantage of approximately 5% at five 
years, a figure that has since been repeated in a larger meta-analy-
sis.31 In this second report, all but 196 of the 3005 patients included 
received cisplatin, with a 9% improvement in five-year disease free 
survival. Although the former study includes results from unpubli-
shed trials (perhaps undermining the reliability of the dataset used) 
and both analyses freely aggregate data from various clinical trials 
with heterogeneous combination cisplatin-based regimens, neoadju-
vant chemotherapy appears to be largely beneficial.
But platinum-based chemotherapeutics are not without poten-
tial toxicity; indeed, single agent cisplatin has been associated 
with worse outcomes than surgery alone.30 However, a systema-
tic review of neoadjuvant MVAC chemotherapy only attributes 
1.1% of deaths to this platinum-containing regimen.32 Equally, 
evidence from the metastatic setting has shown that GC (gem-
citabine and cisplatin) can produce similar response rates at 
reduced toxicity and, as such, may be of use pre-operatively.33 
Several small non-randomised studies have lent support to the use 
of GC. For example, one phase II trial of 22 pre-cystectomy patients 
found a combined partial and complete radiographic response in 
70% of muscle invasive TCCs treated with GC.34 Of the 15 individuals 
that went on to have surgery, pathological complete response was 
evident in 4 (26.7%) of specimens. Median survival was 36 months 
with no deaths attributed to chemotherapy. Similar results have 
been reported elsewhere.35 Although these studies may reasonably 
reassure that GC may provide a practical alternative to MVAC, neo-
GC has yet to be validated in prospective, randomised clinical trials.
Indeed, more recent studies have supported the use of pre-operati-
ve “accelerated” MVAC (under hematopoietic growth factor covera-
ge) in muscle invasive disease.36 This dose dense approach minimi-
ses the delay to definitive treatment imposed by more protracted, 
conventional MVAC or GC therapies and – at present – may be con-
sidered the optimal regimen for patients eligible for cisplatin-based 
chemotherapeutics. Patients deemed unsuitable for typical cisplatin 
regimens may either receive less intense doses in a modified sche-
dule (with or without nephroprotection), or avoid cisplatin altoge-
ther. This is usually achieved by substituting carboplatin for cispla-
tin, although the efficacy of this alternative remains controversial.37
Overall neoadjuvant chemotherapy is associated with a slight survi-
val advantage for muscle invasive bladder cancer. However, it does 
not allow for the selection of patients most likely to benefit and can 
only be systematically provided at the known risk of overtreatment. 
Metastatic disease shows chemoresistance in approximately 40-60% 
of cases and it is not unreasonable to assume that locally advan-
ced TCC will show similar rates of non-responsiveness. Therefore, 
neo-chemotherapy may be considered as a standard of care, althou-
gh clinicians and patients should still be able to elect for definitive 
local therapy with the option of post-operative chemotherapy.18
Adjuvant chemotherapy
As in neo-chemotherapy, the principle of adjuvant drug adminis-
tration is to eliminate occult metastases beyond the margins of 
local therapy. It provides two further key theoretical benefits: first-
ly, definitive treatment is not delayed and, secondly, therapy type 
can be based upon defined pathological criteria. The ability to risk 
stratify is key, as those most likely to benefit appear to be those at 
greatest risk of relapse.38 Indeed, adjuvant chemotherapy may be 
especially indicated in certain high-risk patient groups, including 
those demonstrating residual node and margin positive disease.
One obvious issue with adjuvant approaches is whether patients 
are sufficiently fit following surgery. Two different studies report 
post-cystectomy complications in 30-58% of cases, potentially 
delaying the timely administration of systemic therapy.39,40
Several trials have examined the role of adjuvant chemotherapy in 
muscle invasive disease, producing mixed results. One early trial 
suggested that post-operative chemotherapeutics were associated 
with improved time to progression, cancer regression and overall 
survival parameters within three years; yet the same trends were 
not seen at five years.41 This was, however, only a small study of 
91 patients, further confounded by non-standard chemotherapy re-
gimens and poor application of treatment (fully a quarter of those 
randomised to the treatment group never received chemothera-
py).41 Similar issues were encountered in two further trials, both of 
which were abandoned after inadequate accrual.42,43 Although these 
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studies also demonstrated advantageous progression free survival 
outcomes (HRs of 2.84 and 2.84, respectively), the results are based 
upon <100 patients. Ethically too, these studies have been criticised 
– primarily for failing to treat those in the observation-only group 
undergoing relapse. Long-term follow-up has addressed these con-
cerns and (with a further 117 patients added to the dataset) conti-
nue to demonstrate a marked benefit to adjuvant therapy. 
A meta-analysis of six such RCTs collated results from 491 pa-
tients, revealing an absolute survival improvement of 9% at three 
years (HR 0.75; p=0.019).44 Although these data demonstrate the 
feasibility and safety of adjuvant drug administration, under-
powering and inconsistent methodologies prevent the authors 
from recommending this type of chemotherapy as standard.
Another issue is that many early studies were closed after inte-
rim analysis. For example, the EORTC 30994 phase III trial has yet 
to publish its results (although it too was terminated after poor 
accrual). Interestingly, this study design permitted the use of 
MVAC or GC chemotherapy, at the physician’s discretion. Recent 
research has suggested no statistically significant benefit to GC 
over observation in the adjuvant setting.45 However, with only 194 
patients recruited, even this multicentre trial was underpowered 
to show the impact of treatment on any endpoint assessed.
There appears to be no compelling role for non-platinum based 
chemotherapy post-operatively. Gemcitabine alone in patients 
deemed unsuitable for cisplatin therapy produced a trend towards 
improved survival and disease-free progression when compared 
to surveillance alone, but neither outcome measure reached signi-
ficant thresholds in a recent trial.46 Similarly, single-agent cisplatin 
has yet to be validated post-operatively. For example, one small 
prospective study failed to detect a survival advantage at five 
years when compared to expectant observation.47
Overall, there appears to be low quality evidence to support the 
utility of adjuvant chemotherapy for locally advanced disease.48 
Therefore, patients with high-risk cancer and/or pathological node 
involvement who fulfill fitness criteria (and who are willing to ac-
cept known toxicity risks without proven survival benefit) might be 
considered candidates for post-operative treatment. Yet a recent 
systematic review failed to demonstrate improved survival outco-
mes – even in selected subgroups with extravesical malignancy.49 
Identifying those individuals deemed ‘high-risk’ therefore presents 
particular challenge. One novel idea revolves around selection by 
p53 status (with several retrospective studies suggesting that p53 
changes may be prognostic for TCC recurrence and adjuvant MVAC 
efficacy). Immunohistochemistry for p53 expression segregated one 
study population into two groups, either managed conservatively 
or with three cycles of chemotherapy.50 Although the authors note 
a high-rate of non-compliance with the original study design, p53 
status appeared to have no meaningful effect on endpoint outcomes.
Radiotherapy
The potential advantages of radical radiotherapy as definitive treat-
ment include bladder preservation, avoidance of surgery and intact 
sexual function. Observational studies suggest that this modality 
provides five-year survival rates in the region of 28-50%,with suc-
cessful salvage cystectomy in ~20% of failed cases.51,52 Although di-
rect comparison with radical cystectomy is challenging, large surgical 
and radiotherapy series report similar long-term survival outcomes.53
The marginal superiority of scheduled surgery is supported by 
two meta-analyses. In the first, three RCTs demonstrate a fi-
ve-year survival benefit to pre-operative radiotherapy and plan-
ned cystectomy over radical radiotherapy with secondary salva-
ge cystectomy.54 A second Cochrane review corroborates these 
data, although the calculated odds ratio of 0.71 was sufficient 
only to suggest a trend rather than significance.55 However, the 
advancing age of these particular studies questions whether 
their findings can be applied to more modern techniques.
No RCTs directly compare radiotherapy to chemotherapy as sin-
gle modalities in bladder cancer. However, one early phase II 
study demonstrated a modest advantage to chemoradiotherapy 
over radiotherapy alone, both in terms of ten-year survival and 
bladder preservation rates.56 Should patients prefer radical ra-
diotherapy with the intention of bladder sparing, it is important 
that they appreciate an increased risk of complications during 
salvage cystectomy. For example, one small study of 23 patients 
reported higher complication rates in those with a history of ex-
ternal beam irradiation versus a control matched planned-cys-
tectomy group (48% vs. 26%; p<0.045).57 Thus, cystectomy after 
failed radiotherapy comes with a recognized morbidity risk.
As in chemotherapeutic approaches, it would be of value to be able to 
identify those patients most likely to benefit in advance. One retros-
pective analysis of 342 patients with a median 7.9-year follow-up hi-
ghlighted tumour multiplicity (p<0.001), ureteric obstruction (p=0.001) 
and higher T stage (p=0.004) as independent prognostic factors in 
relapse rates.58 Those patients with these features might be better 
discouraged from radical radiotherapy, whereas younger patients 
with high-grade exophytic tumours appear most likely to respond. 
Further research might aim to advance our understanding of the-
se predictive markers, or investigate optimal dose, fractionation 
and scheduling considerations in treating locally invasive disease. 
Although a recent phase III trial (BC2001) assessing the viability 
of reduced high-dose volume radiation therapy failed to formally 
demonstrate noninferiority of locoregional control and a reduced 
side effect profile, additional studies in this area are required. For 
example, the theory that ‘accelerated radiotherapy’ minimises re-
population by surviving clonogens has yet to be rigorously tested.59 
If radiotherapy is to be delivered with curative intent, the European 
Society for Medical Oncology (ESMO) advises that external beam radio-
therapy should be delivered with 3D conformal or intensity-modulated 
techniques, ideally under image guidance.18 Typically, this would be pro-
vided in conjunction with a multimodal bladder-preserving approach.
Synchronous Chemoradiotherapy: Bladder Preservation
Radiotherapy alone is a recognized bladder-sparing alternative 
to cystectomy in patients with muscle-invasive disease, yet it 
remains associated with a relatively high rate of incomplete res-
ponse or local recurrence. Synchronous chemoradiotherapy may 
therefore have advantages over radiotherapy alone and may be 
especially useful in the treatment of those patients unfit for 
major surgery. This is supported by evidence from other primary 
cancer sites, including cervical and anal malignancies.60,61
A recent multicentre phase III trial demonstrated that that con-
comitant chemotherapy (with fluorouracil and mitomycin C) and 
radiotherapy significantly improved locoregional control of mus-
cle-invasive disease when compared with radiotherapy alone.62 The 
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addition of chemotherapy to standard-dose radiotherapy was as-
sociated with a relative reduction of 33% in the risk of locoregional 
recurrence and almost 50% in invasive recurrence. Improved loco-
regional control was achieved with only modest increases in toxic 
effects that did not achieve statistical significance with respect to 
grade 3 or 4 outcomes. Long-term follow up revealed a clear ad-
vantage for those patients randomised to the chemoradiotherapy 
group: at 5 years, overall survival rates were 48% in the experimen-
tal arm versus 35% for those receiving radiotherapy alone. This was 
achieved without increased rates of salvage cystectomy. Further re-
search might seek to establish whether synchronous chemoradio-
therapy is preferable to radical cystectomy as definitive treatment.
This study also contributes two further important observations. 
Firstly, that the benefits of synchronous chemoradiotherapy were 
independent of a history of neoadjuvant chemotherapy – sug-
gesting that neoadjuvant and concomitant chemotherapy confer 
separate benefits on distant and local control, respectively. Se-
condly, fluorouracil and mitomycin C in combination are effective 
radiosensitising agents and may be considered for patients unfit 
for cisplatin-based therapies. This adds to previously proposed 
alternatives to radiosensitisation based on tumour hypoxia, typi-
cally induced by the use of nicotinamide and carbogen.63 Toge-
ther, these trials suggest that it may be time to re-evaluate the 
preference for surgery over bladder-sparing options, particularly 
in those patients at high-risk for surgical complications.
Trimodal Therapy: Bladder Preservation
Trimodality treatment – i.e. combining chemoradiotherapy with 
bladder-sparing surgical options – may also represent a viable 
alternative to radical cystectomy in muscle-invasive bladder can-
cer. For example, two prospective studies in which chemoradio-
therapy was augmented by transurethral resection demonstrated 
that this approach could be safely applied in selected patients.64,65 
Accurately identifying those individuals most likely to benefit may 
well be difficult, although tumour grade and status after the initial 
resection appear to be important prognostic factors.65 
Bladder-preserving multimodal approaches demand a high level 
of multidisciplinary cooperation and patient compliance. Meticu-
lous long-term surveillance is required to detect intravesical tu-
mour recurrences and this should be considered when offering 
bladder-sparing options. This decision may be further informed 
by several clinical criteria, including: early tumour stage, a visibly 
complete or maximally debulking TURBT, absence of associated 
carcinoma in situ (CIS) and adequate bladder capacity and func-
tion.66 If persistent or recurrent disease is identified during respon-
se evaluation or follow-up, prompt salvage cystectomy is required.
Discussion
Even with accurate staging information, the appropriateness of 
various different management options remains contentious. For 
example, the National Comprehensive Cancer Network (NCCN) 
and NHS guidelines detail at least four separate care plans for 
the treatment of primary cT2 disease, summarized in Table 2.67 
This highlights the need for individually tailored therapy, with 
consideration given to factors such as age and comorbidity, 
as well as patient preference. In the absence of convincing 
evidence to support one approach over another, it is perhaps 
this last component that primarily directs therapeutic strategy.
NCCN and ESMO guidelines both advocate radical cystectomy with 
extended lymphadenectomy as the standard treatment for muscle 
invasive bladder cancer without nodal involvement.18,68 Those pa-
tients with a good performance status and intact organ function 
should be strongly considered for neoadjuvant cisplatin-based com-
bination chemotherapy, whereas those unfit for surgery should be 
considered for radiotherapy either with or without chemotherapy. A 
small minority of patients (<5%) with a solitary T2 lesion in a suitable 
location without concurrent CIS may be eligible for partial cystec-
tomy, usually in conjunction with neoadjuvant chemotherapy. Partial 
cystectomy is not an option for patients with T3 disease or above. 
In both post-cystectomy patients and those pursuing bladder-spa-
ring options, follow-up is an essential component of long-term ma-
nagement, although protocols vary worldwide.18,68 As a minimum, 
urine cytology and imaging of the chest, abdomen and pelvis should 
be performed every 3 to 6 months for 2 years and then as clinically 
indicated. Routine bloods include creatinine, electrolytes and liver 
function tests. Urethral wash cytology is recommended if urethrec-
tomy has not been carried out and/or there is a history of CIS.
Follow-up of patients opting for partial cystectomy or other 
bladder-sparing approaches is the same as for radical cystec-
tomy, except that these individuals require additional 3-mon-
thly surveillance by cystoscopy (usually with selected mapping 
biopsies) for the first 2 years at least. Continued monitoring for 
recurrence is especially important, as most are superficial and 
therefore readily amenable to endoscopic treatment.
Conclusion
The management of muscle invasive bladder cancer remains con-
troversial. The advent of better profiling methods using high throu-
ghput technologies might aid in staging, prognosis and selection 
of optimal treatment approaches;69-71 until then, management pa-
thways are guided by an often inconsistent and unclear literature 
base. However, the value of reliable research is as much in guiding 
the patient as the clinician. Protocols for invasive urothelial cancers 
incur known morbidity and mortality risks and, ultimately, informed 
patients must be involved in the decision-making process.
Luck J. The Role of Chemotherapy and Radiotherapy in the Surgical Management of Muscle Invasive Bladder Cancer
Treatment Option Notes
Radical cystectomy with urinary diversion Strongly consider neoadjuvant cisplatin-based combination chemotherapy
Segmental/partial cystectomy Consider neoadjuvant cisplatin-based combination chemotherapy
Selective bladder sparing following maximal TURBT Consider concurrent radiotherapy and chemother-apy ± salvage cystectomy
TURBT alone
   or radiotherapy alone
   or chemotherapy alone
Extensive comorbidities/poor performance status
Table 2. Summary of Primary Care Protocols for cT2 Disease.
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